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Abstract
Background: The purpose of this study was to assess the
accuracy of double-contrast magnetic resonance (MR)
imaging for the treatment response evaluation of hepa-
tocellular carcinoma (HCC) in cirrhotic liver after
transarterial chemoembolization (TACE).
Methods: Twenty-two patients with 30 HCC nodules
treated by TACE underwent double-contrast MR imag-
ing 1 month after treatment. MR images were obtained
before and after the sequential administration of super-
paramagnetic iron oxide (SPIO) and gadopentetate
dimeglumine contrast agent within the same imaging
session. Two observers retrospectively assessed all
treated nodules for evidence of residual viable tumor
after TACE. The diagnostic performance of gadolinium-
enhanced, SPIO-enhanced, and double-contrast en-
hanced images was calculated. Histopathological and
angiographical findings served as standard of reference.
Receiver operating characteristic curves and areas under
the curves (Az) were calculated.
Results: Double-contrast technique (Az = 0.95) was
significantly (p = 0.036) more accurate than SPIO-
enhanced technique (Az = 0.92) and gadolinium-en-
hanced technique (p = 0.005) (Az = 0.81) in viable
tumor detection after TACE. Double-contrast technique
was significantly more sensitive (92%) than SPIO-
enhanced technique (80%) and gadolinium-enhanced
technique (68%). Kappa values for interobserver agree-
ment ranged from 0.67 to 0.87 and were significantly
different from zero (all p < 0.001).
Conclusions: Compared to gadolinium-enhanced and
SPIO-enhanced techniques, double-contrast technique
significantly improves the detection of viable tumor in
HCC after TACE.
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Hepatocellular carcinoma (HCC) is the most common
primary liver malignant tumor. Although, either liver
transplantation or surgical resection is the best curative
option for HCC, these treatments are offered to a limited
patient population because of the lack of hepatic reserve
or because of the high rate of HCC progression while the
patients are on the transplantation list [1].
Transarterial chemoembolization (TACE) is widely
used in the treatment of patients who will not beneﬁt
from curative approaches or as a bridge to liver trans-
plant. According to Barcelona-Clinic Liver Cancer group
(BCLC) patients with early stages (i.e., one or a maxi-
mum of three HCC nodules < 3 cm) and good liver
function should undergo tumor resection, transplanta-
tion or percutaneous treatment (i.e., percutaneuos etha-
nol injection or thermoablation) [2]. Child-Pugh A or B
patients beyond these tumor stages may benefit from
chemoembolization.
Most centers perform computed tomography (CT)
(unenhanced and dynamic-enhanced) for TACE response
evaluation. Themost frequently used evaluation criteria is
tumor necrosis deﬁned as the absence of nodule
enhancement on contrast-enhanced studies and the
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amount of iodized oil emulsion storage on unenhanced
scans. However, the nodules which were treated by TACE
display areas of high attenuation on unenhanced CT
images due to the iodized oil deposition, which results in
difﬁculties with regard to the analysis of the enhancement
pattern of the nodules following contrast administration.
Moreover, tumor necrosis deﬁned by the extension of io-
dized oil emulsion is probably not a good parameter since
it has been shown that iodized oil retention does not
always indicate necrosis [3].
Double-contrast MR imaging consists on the
administration of superparamagnetic iron oxide (SPIO)
and gadopentetate dimeglumine contrast agents in the
same imaging session. By combining the enhancement
pattern of the nodules after gadolinium administration
on one hand and the tissue-speciﬁc information obtained
after SPIO administration on the other, this technique
has been demonstrated to improve the detection of HCC
nodules in cirrhotic livers [4]. We hypothesized that the
double-contrast MR technique would improve the
detection of viable tumor after TACE and a retrospective
multiobserver analysis involving our patients treated by
TACE was performed.
The main objective of this study was to assess the
accuracy of double-contrast magnetic resonance (MR)
technique performed one month after TACE for the
treatment response evaluation of HCC in cirrhotic liver.
The secondary objective of this study was to describe
the signal intensities of nodules with versus without
viable tumor on unenhanced, SPIO-enhanced, and
Gd-enhanced images.
Materials and methods
Patients
Between July 2001 and June 2004, 65 patients with HCC
underwent TACE at our institution. Of these patients we
included in our study only those patients who fulﬁlled the
following criteria: ﬁrst, the patients underwent double-
contrast MR imaging one month after TACE without
any intervention in the meantime; and second, histolog-
ical or angiographical ﬁndings were available as standard
of reference. Forty-three patients did not fulﬁll these
criteria: 26 patients underwent double-contrast MR
imaging later than one month after TACE, 11 patients
had not undergone double-contrast MR imaging after
TACE, and in six patients there were no angiographical
or histological ﬁndings as standard of references.
Twenty-two patients (16 men, 6 women, mean age 57.8
years, age range 24–74 years) fulﬁlled these criteria.
Fourteen patients had undergone one TACE session,
seven had undergone two, and one had undergone four
chemoembolization sessions. All patients had biopsy-
proved liver cirrhosis: posthepatitis C in nine patients,
posthepatitis B in ﬁve patients, alcohol-induced cirrhosis
in six patients, and mixed etiology in two patients.
Among the 22 patients, TACE was performed in 30 HCC
nodules and these nodules were the focus of this study.
Seventeen patients had one nodule, three patients had
two nodules, one patient had three nodules, and another
patient had four chemoembolized nodules. Three pa-
tients with one nodule were treated in two sessions of
segmental chemoembolization. In all patients with two
nodules chemoembolization was carried out separately
for each nodule by segmental injection of iodized oil
emulsion. The patient with three nodules underwent two
different sessions of treatment which consisted of one
segmental embolization for one nodule and one lobar
embolization for two nodules. The patient with four
nodules underwent four different sessions represented by
three segmental chemoembolizations for one nodule and
one lobar chemoembolization for three nodules. Double-
contrast MR images were obtained 27–30 days (mean
28 days) after each session of segmental or lobar TACE
in 18 patients (14 patients with one nodule, one patient
with three nodules, and three patients with two nodules).
In the three patients with one nodule who underwent two
sessions of treatment the MR images were obtained 27–
29 days after the second chemoembolization. In the pa-
tient with four nodules the MR images were obtained
30 days after the third TACE for one nodule and 29 days
after lobar TACE for the remaining three nodules. The
long axis diameter of the nodules ranged from 12 to
74 mm (mean 31.1 mm) as measured on T1-unenhanced
images.
Our institutional review board does not require
patient approval or informed consent for reviewing pa-
tient images. Patient rights are protected by a law that
requires patients to be informed at examination time
about the possibility that their images might be used for
scientiﬁc purposes.
MR imaging
All images were obtained using a 1.5-T scanner (Signa
Echospeed or Excite HD, GE Healthcare, Waukesha).
The imaging protocol included a transaxial respiratory-
triggered T2-unenhanced fast spin-echo (FSE) sequence
[repetition time (TR)/echo time (TE) = 3500–5714/99–
106 ms; echo-train length (ETL) 12; 2 NEX; ﬁeld-of-view
(FOV) 32–35 · 22–24 cm; matrix, 256 · 256; section
thickness, 6–8.0 mm; intersection gap, 2.0 mm] and
transaxial T1-unenhanced fast spoiled gradient-recalled
echo (FSPGR) sequences in- and out-of-phase during
suspended respiration (TR/TE = 150–200/4.2–4.4 ms
for in-phase acquisition and TR/TE = 120–180/1.5–
2.2 ms for out-of-phase acquisition; ﬂip angle, 60; 1
NEX; FOV, 32–35 · 22–24 cm; matrix, 256 · 192 sec-
tion thickness, 6.0–8.0 mm without spacing).
After obtaining the unenhanced sequences, 1.4 ml of
SPIO ferucarbotran (Resovist, Schering AG, Berlin,
Germany) was administered in all patients as an i.v.
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bolus (corresponding to 0.7 mmol Fe) followed by 20 ml
saline flush. After 15–20 min, transaxial T2-weighted
FSE sequences were performed with the same parameters
as described above for T2-unenhanced images. The pa-
tients remained in the scanner throughout the examina-
tion. However, it was decided to perform the post-
contrast examination with parameter settings optimized
during a prescan performed after contrast-administra-
tion to account for the changes in signal intensity and
to attempt to produce best image quality in each scan.
Finally, a transaxial dynamic frequency-selective fat
saturated T1-weighted two-dimensional FSPGR MR
sequence in arterial, portal-venous and extracellular
phase was performed (TR/TE = 150–170/1.4 ms; flip
angle, 60; 1 NEX; FOV, 32–35 · 22–24 cm; matrix,
256 · 192; section thickness, 6.0–8.0 mm without spac-
ing). The delay between Resovist administration and
dynamic T1-weighted MR sequence was between 23 and
28 min. Gadopentetate dimeglumine was administered as
an i.v. bolus at a dose of 0.2 ml/kg bodyweight
(0.1 mmol/kg bodyweight) with a flow rate of 2 ml/s
followed by a 20-ml saline flush at the same flow rate
using a power injector (Spectris, Medrad, Indianola,
PA, USA). The injection time ranged between 6–10 s.
The dynamic T1-weighted sequences were obtained with
the same parameters as described above for the T1-
unenhanced sequences. To ensure proper acquisition of
the hepatic arterial phase images, bolus timing was per-
formed using 1 ml of gadopentetate dimeglumine.
Abdominal aorta was scanned once per second using a
single slice transaxial FSPGR sequence repeatedly
acquired to observe the wash-in of the gadopentetate
dimeglumine contrast agent into the abdominal aorta [5].
The mean scanning delay of the arterial phase was
approximately 18 s (range 14–29 s). Portal-venous phase
and extracellular phase imaging were performed 60
and 180 s, respectively, after injection of the contrast
medium.
TACE protocol
The decision of performing TACE was based on clinical
and imaging criteria and TACE was performed in pa-
tients who were not suitable for surgical treatment or
patients who were waiting for liver transplant. The
diagnosis of HCC was histological proved in 20 nodules.
In ten nodules the diagnosis was based on correlation
between imaging ﬁndings (MR imaging and DSA) and
clinical data, including the alpha-fetoprotein level. Child
C disease, tumor thrombus in the main left or right portal
trunk, or extrahepatic metastasis was considered contra-
indication for chemoembolization. TACE was performed
with a digital angiography unit (Integris 5000; Philips,
Eindhoven, The Netherlands). Standard angiography
was obtained with a 5F-curved endhole catheter intro-
duced in the proper hepatic artery if no anatomic variant
was present. If not, the replaced hepatic arteries were
selected. Embolization was carried out by segmental or
lobar injection of iodized oil emulsion (Lipiodol; 5–
10 mL, Guerbet, Aulnay-sous-Bois, France) and doxo-
rubicin hydrochloride (Adribastin, 40–50 mg, Pﬁzer,
Switzerland) followed by PVA particles (250–350 lm).
After embolization, an angiographic study of the liver
was performed to conﬁrm tumor devascularization.
TACE procedures were performed by a single radiologist.
Image analysis
Image analysis was performed on a dedicated worksta-
tion (Advantage Windows 4.1; GE Healthcare, Wauke-
sha, WI, USA). Two experienced radiologists in
abdominal imaging (reader 1 with 10 years of experience
and reader 2 with 5 years of experience) separately as-
sessed all imaging data. Both observers were blinded to
clinical data but were informed about location of treated
nodules (by giving the number of the corresponding
Couinauds liver segments). Regarding those patients
with more than one nodule in the same segment, the
readers were asked to differentiate the nodules based on
the long axis diameter. The smallest nodule within the
segment was considered the ﬁrst-assessed nodule.
Patients were randomized and three sets of images were
presented at reading sessions in different order for each
reader: the unenhanced and gadolinium-enhanced ima-
ges (gadolinium technique); the unenhanced and SPIO-
enhanced images (SPIO technique), and the unenhanced,
SPIO-enhanced and gadolinium-enhanced images (dou-
ble-contrast technique). There was a two-week interval
between each reading session.
Signal intensity and enhancement patterns
Each nodule was assessed regarding the signal intensity
and enhancement features. The signal intensity was ﬁrst
assessed on T1-unenhanced in-phase and T2-unenhanced
FSE images relative to surrounding parenchyma as fol-
lows: hypointense, isointense, and hyperintense (homo-
geneous or inhomogeneous). On gadolinium technique
the nodules were assessed as nodules with or without
hypervascular areas. A hypervascular area was deﬁned as
a lesion that displayed a visibly early enhancement on
arterial phase images (greater than that of adjacent
parenchyma or greater than that of nodule on precon-
trast images) followed by a wash-out during later phases.
On SPIO technique both readers were asked to match the
signal intensity of the treated HCC relative to sur-
rounding liver parenchyma on T2-weighted images
before and after SPIO administration to one of the fol-
lowing patterns: isointense nodules and hyperintense
nodules on T2-unenhanced images in which the signal
intensity decreases after SPIO administration; nodules
homogeneous hypointense before as well as after SPIO
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administration; hypointense nodules relative to liver on
T2-unenhanced images which displayed areas of hyper-
intensity on T2-weighted images after SPIO administra-
tion; and ﬁnally, isointense or hyperintense nodules on
T2-unenhanced images which did not show a reduction
in signal intensity on T2-weighted images after SPIO
administration. In this analysis of the T2-characteristics
on unenhanced and SPIO-enhanced T2-weighted FSE
images we included only those hyperintense lesions
whose T2-signal was different from cerebral spinal ﬂuid
since it is known that hyperintense signal similar to CSF
in treated nodules may correspond to liqueﬁed necrosis
[6].
Diagnostic performance
A ﬁnal assessment was made by both readers regarding
the residual tumor presence or absence by using the cri-
teria showed in Table 1 on each technique separately.
For each assessment a 5-point confidence scale was
assigned: 1-definitely no viable tumor; 2-probably no
viable tumor; 3-indeterminate; 4-probably viable tumor;
5-definitely viable tumor.
Standard of reference
Conﬁrmation of the presence or absence of viable tumor
was established by histological ﬁndings (transplantation,
autopsy or tumor resection), or by DSA ﬁndings. The
pathologist was notiﬁed of location of all nodules that
had undergone double-contrast MR imaging after TACE
and the gross specimens were reviewed by one radiologist
together with the pathologist. DSA was performed in
those cases with suspicion of viable HCC after TACE
based on serum alpha-fetoprotein level or double-con-
trast MR images. DSA was considered an effective
method for nodule evaluation since the presence of hy-
pervascularized areas indicates residual HCC [6, 7]. The
intervals between double-contrast MR examination and
standard of references were as follows: 46–431 days for
transplantations (mean 117.40 days); 91 and 202 days
for autopsies; 50 days for tumor resection; and 20–
340 days (mean 122.87 days) for angiographies.
Statistical analysis
Descriptive results for assessment of signal intensity and
enhancement pattern for each observer are reported in
absolute and relative numbers. Interobserver agreement
was assessed using Cohens kappa, and kappa values
were tested for signiﬁcant difference than zero [8]. A k
value of 0 indicates poor agreement, a value of 0.01–0.20
indicates slight agreement, a value of 0.21–0.40 indicated
fair agreement, a value of 0.41–0.60 indicated moderate
agreement, a value of 0.61–0.80 indicated substantial
agreement, and a value of 0.81–1.00 indicated an almost
perfect agreement [8]. Sensitivity, specificity, and accu-
racy for viable tumor detection were calculated for each
reader and each MRI technique. The statistical signifi-
cance of any difference between gadolinium-enhanced,
SPIO-enhanced and double-contrast enhanced tech-
niques was assessed using the Wilcoxon and Student t
test. For each technique (gadolinium, SPIO, and double-
contrast technique) binomial receiver operating charac-
teristic (ROC) curves were calculated. The area under the
ROC curve (Az) was used to indicate the overall per-
formance of each imaging techniques. Sensitivity, speci-
ficity and accuracy of the imaging criteria for the
presence of viable tumor with each MR technique were
assessed for only those nodules that were assigned a
confidence rating of 1 or 2 versus 4 or 5. All statistics
were calculated using the SPSS Software (SPSS Inc.,
Chicago, IL, USA).
Results
Standard of reference
A viable tumor was found in 26 of 30 nodules (87%). The
standard of reference in these cases consisted of histo-
pathological analysis (following transplantation-12 nod-
ules, and autopsy-2 nodules), and DSA ﬁndings in 12
nodules. In four nodules (13%) no viable tumor was
found at histopathological analysis.
Signal intensity and enhancement patterns
Absolute and relative numbers for signal intensity and
enhancement pattern assessment for each observer, as
well as kappa values for the interobserver agreement are
reported in Table 2. Kappa values for interobserver
agreement ranged from 0.67 to 0.87 and were signifi-
cantly different from zero (all p < 0.001).
Enhancement pattern on gadolinium-enhanced images
All nodules (15 from 30) that were assessed as hyper-
vascular by both readers were nodules with viable tu-
mor at standard of reference (DSA in ﬁve nodules and
histological ﬁndings in ten nodules) (Fig. 1). Among the
nodules assessed as nodules without hypervascular
areas (ten for both readers) there were seven false
negatives results. The standard of reference was DSA in
three nodules and histological findings in seven nodules.
In all these cases the nodules displayed an inhomoge-
neous hyperintense signal on T1-unenhanced images
(Fig. 2). Both readers considered five nodules as inde-
terminate regarding the arterial enhancement. Four
nodules were with viable tumor at standard of refer-
ence. In all these four nodules the standard of reference
was DSA.
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Signal intensity pattern on SPIO-enhanced images
All nodules (18 for reader one and 20 for reader 2)
that displayed hyperintense areas with no reduction in
signal intensity on T2-weighted images after SPIO
administration were with residual viable tumor (Fig. 3).
DSA was the standard of reference in nine nodules.
This criterion was especially useful in the cases of the
false negative results on gadolinium-enhanced tech-
nique (e.g., hyperintense nodules on T1-unenhanced
Table 2. Signal intensity and enhancement pattern assessment of HCC treated with TACE
MR images Pattern
R1 no
(%)
R2 no
(%)
k-value
(95% CI) P-value
Nodules with
viable tumor
at SOR
Unenhanced T1 Total 30 (100%) 30 (100%) 0.87 (0.70–1) <0.001
Hyperintense 17 (57%) 17 (57%) 15
Hypointense 2 (7%) 2 (7%) 1
Isointense 11 (36%) 11 (36%) 10
Unenhanced T2 Total 30 (100%) 30 (100%) 0.67 (0.44–0.90) <0.001
Hyperintense 16 (54%) 16 (54%) 14
Hypointense 7 (23%) 7 (23%) 6
Isointense 7 (23%) 7 (23%) 6
Gadolinium-enhanced
technique
Total 30 (100%) 30 (100%) 0.67 (0.44–0.90) <0.001
Hypervasculara 15 (50%) 15 (50%) 15
Without hypervascular areas 10 (34%) 10 (34%) 7
Indeterminate 5 (16%) 5 (16%) 4
SPIO-enhanced
technique
Total 30 (100%) 30 (100%) 0.75 (0.54–0.95) <0.001
Nodules homogeneous isointense
or hypointense on T2-unenhaced
images which displayed hyperintense
areas on T2-weighted images after
SPIO administrationb
2 (7%) 4 (13%) 4
Nodules isointense or nodules with
hyperintense areas on T2-unenhanced
images with no signal reduction after
SPIO administrationb
16 (53%) 16 (53%) 16
Nodules homogeneous hypointense before
and after SPIO administrationc
6 (20%) 5 (17%) 1
Nodules isointense or with hyperintense
areas on T2-unenhanced images which
decrease in signal after SPIO
administrationd
3 (10%) 3 (10%) 2
Indeterminate 3 (10%) 2 (7%) 3
R1, reader 1; R2, reader 2; SOR, standard of reference
aAreas with a rapid enhancement on arterial phase images (greater than that of adjacent parenchyma or greater than that of nodule on precontrast
images) followed by a wash-out during later phases on gadolinium-enhanced technique
bAreas without SPIO uptake which is considered as an indicator of malignancy (4)
cNodules with coagulative necrosis (32)
dAreas with SPIO uptake which is considered as an indicator of the viable tumor absence (4)
Table 1. Criteria for the presence or absence of viable HCC after TACE with each MR technique
MR technique Nodules with residual viable tumor Nodules without residual viable tumor
Gadolinium-enhanced Nodules with hypervascular areasa Nodules without hypervascular areas
SPIO-enhanced Nodules homogeneous hypointense on unenhaced
T2-weighted images which display hyperintense
areas on T2-weighted images
after SPIO administrationb
Nodules homogeneous hypointense on
T2-weighted images before and after
SPIO administrationc
OR OR
Nodules hyperintense or isointense on unenhanced T2-weighted
images with no signal reduction after SPIO administrationb
Nodules hyperintense or isointense on
unenhanced T2-weighted images which
decrease in signal after SPIO administrationd
Double-contrast
enhanced
Nodules assessed as nodules with viable tumor on
gadolinium-enhanced
images OR on SPIO-enhanced images
Nodules assessed as nodules without viable
tumor on gadolinium-enhanced images AND
on SPIO-enhanced images
aAreas with a rapid enhancement on arterial phase images (greater than that of adjacent parenchyma or greater than that of nodule on precontrast
images) followed by a wash-out during later phases on gadolinium-enhanced technique
bAreas without SPIO uptake which is considered as an indicator of malignancy (4)
cNodules with coagulative necrosis (32)
dAreas with SPIO uptake which is considered as an indicator of the viable tumor absence (4)
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images) (Fig. 2). The homogeneous hypointense nod-
ules before and after SPIO administration (6 for reader
1 and 5 for reader 2) were without viable tumor in
four cases (Fig. 4). All nodules which were assessed as
nodules with signal drop after SPIO administration
were nodules with viable tumor at standard of refer-
ence (DSA in one nodule and histological findings
in two nodules). Those nodules in which the readers
were not confident in assigning an established pattern
(indeterminate nodules) were nodules with viable
tumor. DSA was the standard of reference in two
nodules.
Diagnostic performance
Sensitivities, speciﬁcities and accuracies for viable tumor
detection for each observer and each MRI technique are
shown in Table 3. For both readers, double-contrast
technique was more accurate than SPIO-enhanced and
gadolinium-enhanced techniques. There was a significant
difference between double-contrast and SPIO-enhanced
technique (R1, p = 0.032; R2, p = 0.009) and between
double-contrast and gadolinium-enhanced technique
(R1, p = 0.009; R2, p = 0.003). No significant differ-
ences were found between gadolinium-enhanced and
SPIO-enhanced technique (R1, p = 0.454; R2, p =
0.126). ROC curves for viable tumor detection are shown
in Fig. 5. Corresponding Az values for gadolinium-en-
hanced technique were 0.81, for SPIO-enhanced tech-
nique 0.92, and for double-contrast technique 0.95.
Overall performance for double-contrast technique was
significantly higher than gadolinium-enhanced (p =
0.005) and SPIO-enhanced technique (p = 0.036)
regarding detection of viable tumor. No significant dif-
ference for the overall performance of viable tumor
detection was found between gadolinium and SPIO-en-
hanced techniques (p = 0.28).
Discussion
Complete necrosis of HCC is rarely accomplished with
TACE. Therefore different imaging modalities for eval-
uation of TACE efﬁcacy have been described. Many
studies [9–12] have shown that the TACE effectiveness
can be judged based on the degree of iodized oil retention,
as a close correlation between accumulation of iodized oil
emulsion and tumor necrosis has been demonstrated
histologically [13, 14]. A complete retention of iodized oil
emulsion on CT images was correlated with a 98%
necrosis of resected specimen [11]. Imaeda et al. [9] eval-
uated the effectiveness of TACE based on the measure-
ments of attenuation values of the nodules after TACE.
These authors concluded that a cutoff value of 365 HU
corresponded to massive necrosis (>97% of the nodule)
with 89% sensitivity and 73% specificity. A more accurate
evaluation of necrotic areas was obtained by combining
unenhanced CT with contrast-enhanced CT [15, 16]. The
necrotic areas were defined as iodized oil retention areas
and areas with no enhancement on contrast-enhanced
CT. By using these criteria, Okusaka et al. [16], demon-
strated a significant correlation between tumor necrosis
at CT and tumor necrosis rate at histopathology.
Other authors [17–19] evaluated these two criteria as
prognostic markers after TACE. In these studies, a
homogeneous accumulation of iodized oil emulsion
within the tumor on unenhanced-CT images was corre-
lated with a high survival rate [17], while an incomplete
iodized oil emulsion retention was followed by a higher
rate of recurrence 1 year after treatment [18].
Fig. 1. Follow-up MR images of a 60-year-old male with
HCC and liver cirrhosis obtained 29 days following TACE.
A Transverse T1-weighted gradient-echo recalled MR image
(210/1.3) before the administration of contrast agents shows
a hypointense nodule. B Corresponding T1-weighted 2D
FSPGR MR image (150/1.4) obtained 20 s after gadopente-
tate dimeglumine administration demonstrates a marked
arterial enhancement of the periphery of the nodule indicating
viable tumor (arrow). The nodule was considered a nodule
with residual viable tumor and the result was confirmed at
histopathology.
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However, there is some evidence that assessment of
tumor necrosis is probably not a good parameter for
TACE evaluation since the tumor progression was noted
even in nodules completely ﬁlled with iodized oil on
unenhanced-CT [17, 20]. Moreover, Castrucci et al. [6]
have demonstrated that the iodized oil absence in areas
within the nodule does not always correspond to residual
tumor. The patients who underwent TACE may develop
local chemotherapy-induced vasculitis and vascular
occlusions. Therefore, the non-enhancing areas on dy-
namic CT images may represent tumor, necrosis or
fibrosis [21].
In addition to these CT studies there are several
studies with other imaging modalities (ultrasonography
or dynamic contrast-enhanced MR using gadolinium-
compounds) focusing on the residual tumor detection
after TACE [3, 22–25]. Regardless the imaging tech-
nique, the diagnosis of viable HCC after TACE is mainly
based on tumor vascularity, and is defined as an early
arterial enhancing area. Koito et al. [22], using biopsy as
standard of reference, reported a 66.6% sensitivity, a
100% specificity, and 93.6% accuracy for assessing tumor
viability with power Doppler sonography. Doppler
sonography can reveal tumor vascularity independently
of iodized oil emulsion accumulation having an advan-
tage over CT [26]. By using the microbubble contrast
agents, ultrasonography enabled assessment of TACE
efficacy with a sensitivity and a specificity of 94.7% and
80%, respectively, when the results were compared with
dynamic-CT [27].
MRI is increasingly used in HCC follow-up after
TACE. By using dynamic gadolinium-enhanced MR
Fig. 2. Cirrhotic liver in a 58-year-old male with an HCC
nodule in liver segment 4, 27 days after the first TACE. A
Unenhanced transverse T1-weighted 2D GRE MR image
(210/1.2) demonstrates an inhomogeneous hyperintense
nodule compared to the liver parenchyma. B Transverse T1-
weighted 2D FSPGR MR image (170/1.4) obtained 20 s after
gadopentetate dimeglumine administration. Areas of early
arterial enhancement cannot be discriminated within nodule
which appears inhomogeneous hyperintense on either
unenhanced and enhanced images. C Transverse respira-
tory-triggered T2-weighted FSE (5000/99.4 with fat suppres-
sion) at the same level before SPIO administration. The
nodule is hypointense because of coagulative necrosis with a
small hyperintense area at the periphery (arrow). D Trans-
verse respiratory-triggered T2-weighted FSE (5000/99.4 with
fat suppression) at the same level, 15 min after SPIO
administration. Note the hyperintense area with no evidence
of SPIO uptake which becomes more conspicuous at the
periphery of the low signal intensity nodule (arrow). Based on
this pattern, on double-contrast images, the nodule was cor-
rectly assessed as a nodule with viable HCC after TACE.
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imaging, Murakami et al. [28] were able to accurately
assess the TACE efficacy in nine of ten patients using
histopathological findings as standard of reference. In
another study [29], dynamic gadolinium-enhanced MR
imaging showed a sensitivity, specificity and accuracy of
100% for viable tumor detection after TACE. However,
in the study of Kubota et al. [29], histological or angio-
graphical correlations were not available in all patients
and the authors excluded 14 of 84 nodules (17%). These
nodules were considered unsuitable for qualitative
assessment of contrast uptake due to the high signal
intensity pattern on T1-unenhanced images.
In our study, the double-contrast MR technique was
more accurate in viable tumor detection after TACE
compared to gadolinium or SPIO techniques alone. With
dynamic gadolinium-enhanced technique, we obtained a
sensitivity of 68%, a speciﬁcity of 100% and an accuracy
of 72% for viable tumor detection. Although it was
Fig. 3. A sixty-year-old male with liver cirrhosis and with
two HCC nodules in liver segment 1 and liver segment 5,
30 days after the first TACE session. A Transverse respira-
tory-triggered T2-weighted FSE (7500/87.3 with fat suppres-
sion) before SPIO administration. Both nodules are
inhomogenous hyperintense compared to the surrounding
liver parenchyma (arrows). B Transverse respiratory-trig-
gered T2-weighted FSE (7500/87.3 with fat suppression) at
the same level, 15 min after SPIO administration. Both nod-
ules are clearly seen as marked hyperintense areas com-
pared to the unenhanced images (arrows). Both nodules were
considered with residual viable tumor and were confirmed at
standard of reference.
Fig. 4. Cirrhotic liver in a 46-year-old male with an HCC
nodule in liver segment 5, 30 days after the second TACE
session. A Transverse respiratory-triggered T2-weighted FSE
(6667/99.4 with fat suppression) before SPIO administration.
The nodule is well-delineated and homogeneous hypointense
compared to the surrounding liver parenchyma. B Transverse
respiratory-triggered T2-weighted FSE (6667/99.4 with fat
suppression) at the same level, 15 min after SPIO adminis-
tration. The nodule remains homogeneous hypointense
without any hyperintense areas. Note the thin pseudocapsule
which is hyperintense (arrow). The nodule was without viable
tumor at standard of reference.
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reported that iodized oil emulsion produces high signal
areas on T1-unenhanced images just over the ﬁrst few
days following TACE [30], 17 of 30 nodules (56%) were
homogeneously or inhomogeneously hyperintense on
T1-unenhanced images in our study. These lesions were
responsible for most of the false negative results. One
explanation of the high signal intensity of the nodules
after TACE on T1-unenhanced images may be repre-
sented by the coagulative necrosis [31, 32]. Our findings
are in agreement with the results of other studies in which
half of nodules were hyperintense on T1-unenhanced
images after TACE [33]. Results of our study indicate
that the SPIO-enhanced technique was more sensitive
(80%) and accurate (83%) compared to the gadolinium-
enhanced technique (68% sensitivity and 72% accuracy)
without any statistically significant difference. The
diagnosis of viable HCC was based on the signal inten-
sity pattern on T2-weighted images before and after
SPIO administration. The rationale for the fact why
SPIO-enhanced MR imaging may increase the diagnostic
performance for detection of viable tumor might be ex-
plained by the following hypothesis. Immediately after
TACE, in acute phase of cytotoxicity there are areas of
liquefied necrosis which are hyperintense on T2-weighted
images [34]. In a later phase, an area that is completely
embolized by TACE usually demonstrates low signal
intensity on unenhanced T2-weighted MR images (due to
coagulative necrosis) [32]. The signal intensity of these
areas is unchanged on T2-weighted images after SPIO
administration. Hyperintense foci within these hypoin-
tense nodules or along its periphery may represent one
month after TACE viable tumor on T2-unenhanced
images. These hyperintense foci may be barely visible on
T2-unenhanced images. Due to the fact that following
SPIO administration the signal of the surrounding liver
parenchyma decreases, these hyperintense foci are
becoming more conspicuous in particular if they are
located within the periphery of the nodule. The false
negative results were represented by nodules homoge-
neous hypointense on both T2-weighted images, before
and after SPIO administration (2 nodules for reader 1
and one nodule for reader 2). This may be as a result of
the fact that small foci of HCC are only visible at his-
tology [3]. Three false negative results were caused by
nodules with hyperintense areas on T2-unenhanced
images which decreased in signal intensity after SPIO
administration. However, it is known that well-differen-
tiated HCs may contain Kupfer cells and show some
uptake of SPIO. This lesions can be missed on SPIO
technique [35].
In comparison to gadolinium technique and SPIO
technique, double-contrast technique was more accurate
(92%) in viable tumor detection after TACE. By com-
bining the strong vascular enhancement of gadolinium
on one hand and the SPIOs tissue speciﬁc information
on the other, both readers were able to detect viable
tumor in 24 of 26 nodules with viable tumor at standard
of reference. In two nodules assessed as nodules without
viable tumor, small areas of HCC were found at histol-
ogy. Both nodules were hyperintense on T1-unenhanced
images and displayed a decrease in signal intensity on T2-
weighted images after SPIO administration.
We acknowledge the following limitations. We did not
compare MR images with any cross-sectional image
modality performed prior to TACE. Therefore the size of
the treated lesion was not an interpretation criteria.
However, it has been demonstrated that the rate of tumor-
size reduction does no correlate with the therapeutic effect
Table 3. Sensitivity, specificity and accuracy for viable tumor detection for each reader and MRI technique
True-
positive
True-
negative
False-
positive
False-
negative
Indeter-
minate Sensitivity Specificity Accuraccy
MR technique R1
(n)
R2
(n)
R1
(n)
R2
(n)
R1
(n)
R2
(n)
R1
(n)
R2
(n)
R1
(n)
R2
(n)
R1
(%)
R2
(%)
Mean
(%)
R1
(%)
R2
(%)
Mean
(%)
R1
(%)
R2
(%)
Mean
(%)
Gadolinium-enhanced 15 15 3 3 0 0 7 7 5 5 68 68 68 100 100 100 72 72 72
SPIO-enhanced 18 20 4 4 0 0 5 4 3 2 78 83 80 100 100 100 81 85 83
Double-contrast enhanced 24 24 4 4 0 0 2 2 0 0 92 92 92 100 100 100 93 93 93
Fig. 5. ROC curves for viable tumor detection with means of
both observers for gadolinium-enhanced technique, SPIO-
enhanced technique, and double-contrast enhanced tech-
nique. Sequential administration of gadolinium and SPIO
combined resulted in the best performance for detection of
viable tumor after TACE.
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of chemoembolization [15]. The time point of follow-up
and the interval between double-contrast MR examina-
tion and standard of reference can be considered as an-
other limitation. In this study we evaluated the patients
with MR imaging 4 weeks after TACE. A one month
interval after TACE is necessary in order to avoid mis-
takes when evaluating areas with nonspecific iodized oil
emulsion deposition. In this interval iodized oil gradually
washes-out from nonnecrotic areas of HCC and sur-
rounding parenchyma [15]. Regarding the interval be-
tween MR studies and final confirmatory results, we
considered that the presence of viable HCC within a
treated nodule is the result of the progression of residual
tumor after TACE and does not indicate a de novo or a
remote HCC.
We did not make a quantitative assessment of the
signal intensity of the nodules on gadolinium-enhanced
images. This might have improved the gadolinium-en-
hanced technique performance especially for those nod-
ules which were hyperintense on T1-unenhanced images.
However, the signal intensity changes by means of region
of interest (ROI) measurements should be obtained
within suspicious areas of enhancement. Since the exact
localization and extent of these areas are difﬁcult to
evaluate in nodules which are homogeneous or inho-
mogeneous hyperintense on T1-unenhanced images, the
results of signal intensity measurements highly depend
on the location of the ROI. Another potential limitation
might be the fact that the enhancement pattern of the
extracellular contrast medium could have been inﬂu-
enced by the prior administration of the SPIO. Although,
SPIO affects the signal intensity of normal liver paren-
chyma on both T1- and T2-weighted images , this signal
reduction does not inﬂuence the gadolinium enhance-
ment and so the analysis of hypervascular areas is not
affected [35].
A histopathological analysis was not possible for all
nodules and DSA was performed in those cases with
suspicion of viable HCC based on serum alfafetopro-
tein level or double-contrast MR images. In ﬁve
nodules, the suspicion was based on the areas of
hypervascularity on MR images. However, DSA is
considered a reliable imaging modality for assessment
of viable tumor [6, 7]. Finally, the number of nodules
in this study was relatively small, so further studies
with a larger number of nodules are needed to reach a
firmer conclusion.
In conclusion, this study shows that double-contrast
MR technique (i.e., the sequential administration of
SPIO and gadopentetate dimeglumine contrast agents)
may be a useful strategy for the treatment response
evaluation of HCC in cirrhotic liver after TACE. Dou-
ble-contrast MR technique signiﬁcantly improves the
viable tumor detection in HCCs treated with TACE
compared to gadolinium-enhanced and SPIO-enhanced
techniques.
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